The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessAbstract
The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During the time between initiation and completion of the FIDELIO-DKD and FIGARO-DKD trials, numerous rigorous clinical trials demonstrated large kidney and cardiovascular bene fi ts of SGLT2i (Section 1.3 above), and SGLT2i became an established fi rst-line treatment for T2D with CKD.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [143]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prioritization of SGLT2i therapy in high-risk patients such as those with CKD is consistent with the recommendations from other professional societies including the American College of Cardiology (ACC), 142 the joint statement by the ADA and the European Association of the Study of Diabetes (EASD), 143 and the joint guideline by the European Society of Cardiology (ESC) and EASD.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“Somemeta-analyses (5,13,14) suggest the presence of heterogeneity in estimates forMACE andCVdeathwithGLP-1 receptor agonists, although this ismostly due to the results of a single trial with lixisenatide.”
ResultDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citationRosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Cited by
Sorted by citations
Items 901–1,000 of 1,000
CHENG, A. Y. Y., Mottl, A. K., & MAGWIRE, M. L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01796-7 · Cited by 4
Noman, M., Hanif, M., Hameed, A., Babar, M. A., & Qureshi, B. (2025) · PLoS ONE · doi:10.1371/journal.pone.0327661 · Cited by 1
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Management of Diabetes Mellitus: A Review
Singh, V., Yadav, V., Awasthi, V., Yadav, R., Shukla, S., Gupta, D., & Shukla, A. K. (2025) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.4.6.15 · Cited by 1
Amelia, R., Pranata, C., Dewi, T. K., & Nasution, A. M. (2026) · Current Diabetes Reviews · doi:10.2174/0115733998379857251113060856 · Cited by 1
Gao, Q., Li, Y., & Wang, L. (2026) · Food Reviews International · doi:10.1080/87559129.2026.2642794 · Cited by 1
Li, Z., Zhang, S., & Liu, B. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-120259 · Cited by 1
Beyond glycemic control: clinical cardiovascular effects of tirzepatide—a narrative review
Alawad, A. O., Merghani, T. H., Fadelelmoula, T. E. Y., Elamin, N. A., Satti, S., Edris, A., Hakim, A., El-Hindi, R. F., Alhaj-Ali, A. A., Ibrahim, W. E., et al. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261469947 · Cited by 1
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Self-citationMikhail, N. E. (2020) · Archives of Diabetes & Obesity · doi:10.32474/ado.2020.02.000149 · Cited by 1
Baldia, P. H., Marx, N., & Schütt, K. A. (2020) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1117-8446 · Cited by 1
Dashora, U. K., Patel, D., Gregory, R., Winocour, P. H., Dhatariya, K., Rowles, S. V., Macklin, A., Rayman, G. A., & Nagi, D. K. (2020) · British Journal of Diabetes · doi:10.15277/bjd.2020.265 · Cited by 1
Timar, B., Braha, A., Grigorică, L., Gaiţă, L., & Timar, R. Z. (2020) · Timişoara Medical Journal · doi:10.35995/tmj20200101 · Cited by 1
Post-transplant Management in Heart Transplant Recipients: New Drugs and Prophylactic Strategies
Fida, N., Tantrachoti, P., Guha, A., & Bhimaraj, A. (2021) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-021-00933-2 · Cited by 2
Shamsi, N. (2021) · Journal of Endocrinology and Metabolism Research · doi:10.37191/mapsci-2582-7960-2(2)-019 · Cited by 1
Kadowaki, T., Inagaki, N., Watada, H., Sasaki, K., Mori‐Anai, K., Iwasaki, T., & Teranishi, T. (2022) · Advances in Therapy · doi:10.1007/s12325-021-02038-5 · Cited by 1
Modern approaches to the treatment of atrial fibrillation in patients with diabetes mellitus.
Serik, S. A., & Strona, V. I. (2022) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2022.01.069 · Cited by 1
Lee, A. E., Chiu, C., Thian, A., Suann, B., & Gorman, S. (2022) · Frontiers in Environmental Science · doi:10.3389/fenvs.2022.970658 · Cited by 1
Mannucci, E., & Ghetti, G. (2022) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v23i1.1539 · Cited by 1
Assessing the Knowledge and Awareness of Self-Management among Diabetic Patients in Saudi Arabia
Bakhuraysah, M. M., Alsalmi, S. A., Alfadli, S. N., Alotaibi, S. A., Althomali, D. S., Gharib, A. F., Alrehaili, A. A., & Alhuthali, H. M. (2022) · Research Review · doi:10.52845/jmrhs/2022-5-7-5 · Cited by 2
Immunological profile of diabetic foot ulcers: update review
Jassim, M. M. A. (2023) · Muthanna Medical Journal · doi:10.52113/1/1/2023-38-43 · Cited by 1
Complex metabolic–endocrine syndromes: associations with cardiovascular disease
Krentz, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00010-3 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Multimorbidity in nephrotic syndrome
Teplan, V. (2023) · Vnitřní lékařství · doi:10.36290/vnl.2023.028 · Cited by 1
Zhang, L., Pan, C., Yang, X., Jiang, D., & Cao, M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2216453 · Cited by 1
Genetics of Coronary Artery Disease in Diabetes Mellitus
Morieri, M. L., & Doria, A. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_6 · Cited by 1
Zhao, H., Zhao, Z., He, K., Mi, N., Lou, K., Dong, X., Zhang, W., Sun, J., Hu, X., Pang, S., et al. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01256-0 · Cited by 1
Physical Activity and Inflammation
Loretelli, C., D’Addio, F., Nasr, M. B., & Fiorina, P. (2023) · Springer eBooks · doi:10.1007/978-3-031-27192-2_9 · Cited by 1
Wollenhaupt, D., Wolters, J., Aziz, M. S. A. E., & Nauck, M. A. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003296 · Cited by 2
Role of Lifestyle and Stress on Diabetes Mellitus: A Case-Control Study
Harikrishnan, S., Pulate, R., Terrance, S., Shikfa, O., & Sreedharan, J. (2023) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2680 · Cited by 1
Diabetes self-management education
Ojo, I., Ojo, E. F., & Olubiyi, S. K. (2023) · Journal of Integrative Nursing · doi:10.4103/jin.jin_105_22 · Cited by 2
Pușcașu, C. (2023) · FARMACIA · doi:10.31925/farmacia.2023.4.19 · Cited by 1
From a Glycocentric Approach to Prevention of Multi-Organ Damage in Type 2 Diabetes
Grover‐Páez, F., Gómez, A. M., Suárez, A., & Echauri, A. M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002363 · Cited by 2
Christiaens, A., Simon‐Tillaux, N., Thompson, W., Sinclair, A. J., Henrard, S., Boland, B. B., Slaouti, Y., Lekens, B., Bonnet‐Zamponi, D., Tubach, F., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-073081 · Cited by 1
Doğan, N. B., Yilmaz, H., & Kılıçaslan, B. (2023) · Texas Heart Institute Journal · doi:10.14503/thij-23-8196 · Cited by 1
Kim, T., Campbell, D. B., Au, F., Ronksley, P. E., Weaver, R. G., & Campbell, D. J. T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15419 · Cited by 1
Demidova, T. Y., Titova, V. V., & Скуридина, Д. В. (2023) · FOCUS Endocrinology · doi:10.15829/2713-0177-2023-4-23 · Cited by 1
Smid, V., & Dvořák, K. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.013 · Cited by 2
Stachteas, P., Patoulias, D., Popovic, D. S., Athanasiadou, P., & Fragakis, N. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.1.6 · Cited by 1
Could metformin modulate the outcome of chronic murine toxoplasmosis?
Gomaa, M. M., Achy, S. E., & Hezema, N. N. (2024) · Acta Tropica · doi:10.1016/j.actatropica.2024.107339 · Cited by 1
Qiang, W., Yang, F., Liu, L., Dong, R., Sun, Y., Mondal, A., & Guo, H. (2024) · Clinical Case Reports · doi:10.1002/ccr3.9282 · Cited by 1
Zaghloul, N., Awaisu, A., Mahfouz, A., Ali, Z. O., Alyafei, S., & Elewa, H. F. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-024-01828-5 · Cited by 1
Dong, H., Li, X., Gu, Q.-X., Ma, C., Yuan, M., Wang, Z.-Z., Su, J., Xu, L., Chen, C., Ebule, Q., et al. (2024) · Biomarkers in Medicine · doi:10.1080/17520363.2024.2432309 · Cited by 1
Munoz, S. R., Mol, P. G. M., de Vries, F., van Dijk, P. R., Hillege, H. L., Postmus, D., & de Vries, S. T. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s486553 · Cited by 1
Dinčić, M., Čolović, M. B., Todorović, J., Milinković, N., Radosavljević, B., Mougharbel, A. S., Kortz, U., & Krstic, D. Z. (2025) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-025-02098-w · Cited by 1
A Consensus Report on Management of Type 2 Diabetes Mellitus in Iran
Esteghamati, A., Malek, M., Hosseinpanah, F., Hadaegh, F., Afkhami‐Ardekani, M., Meybodi, H. R. A., Dabbaghmanesh, M. H., Ghaemi, F., Jahed, S. A., Kalbasi, S., et al. (2024) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.39.13 · Cited by 1
Christiaens, A., Cochard, A., Tubach, F., Thompson, W., Sinclair, A. J., Henrard, S., Boland, B. B., Slaouti, Y., Lekens, B., Bonnet‐Zamponi, D., et al. (2025) · Age and Ageing · doi:10.1093/ageing/afaf160 · Cited by 2
Alexander, I., Agu, P. C., Udegbe, U. F., Ezeh, E. M., & Nwali, N. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-06556-7 · Cited by 1
Oo, M. M. S., Jayawardana, S., Campbell, A., Aitken, M. L., Patel, K. V., Nasir, K., Mehra, M. R., & Mossialos, E. A. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0005326 · Cited by 2
Trischuk, T., Laubscher, T. A., & Regier, L. D. (2020) · PubMed Central · Cited by 1
Dipeptidyl peptidase 4 inhibitors in modern domestic practice
As, A., Chernikov, N. A., & Knyshenko, O. A. K. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-7-14-18 · Cited by 1
Mannucci, E., Mangia, P. P., & Pradelli, L. (2020) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v21i1s.1490 · Cited by 1
Раннє призначення інсуліну при цукровому діабеті 2-го типу: плюси і мінуси
Jargin, S. V. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.2.2021.230572 · Cited by 1
Rossing, P. R., & Persson, F. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.002 · Cited by 1
Self-citationGlucagon-like Peptide-1 Receptor Agonists (GLP1-RA)
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_26 · Cited by 1
Hamann, A. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00783-3 · Cited by 1
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Selig, L., Blüher, M., & Menzen, M. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00903-7 · Cited by 1
Heart Failure Burden in Diabetes: Can Fenofibrate Provide Additional Hope?
Morieri, M. L. (2022) · Diabetes Care · doi:10.2337/dci22-0012 · Cited by 3
Diabetic Kidney Disease: Identification, Prevention, and Treatment
Caramori, M. L., & Rossing, P. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_7 · Cited by 1
Self-citationFrundi, D., Kettig, E., Popp, L. L., Hoffman, M., Dumartin, M., Hughes, M., Lamy, E., Fru, Y. J. W., Bano, A., Muka, T., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.907385 · Cited by 1
Precision medicine in diabetes - current trends and future directions. Is the future now?
Szczerbiński, Ł., & Florez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00021-6 · Cited by 1
Knobler, H., & Toledano, Y. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa827 · Cited by 1
When and for Whom Should We Use SGLT2 Inhibitors in HFrEF?
Tanaka, A., & Node, K. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.07.009 · Cited by 1
Patoulias, D., Papadopoulos, C. E., Karagiannis, A. I., & Doumas, M. N. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.12.010 · Cited by 1
Sodium-glucose cotransporter-2 inhibitors as first-line pharmacological therapy for type 2 diabetes?
Kuchay, M. S., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102580 · Cited by 1
Which person with diabetes should receive cardioprotective glucose‐lowering medicines?
Bloomgarden, Z. T. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13029
RESPONSE: The Imperative to Change the Delivery of Cardiometabolic Care
Kosiborod, M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.018
Diabetes a kardiovaskulární onemocnění
Karásek, D. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.023
Pre-diabetes and cardiovascular risk: detonating the time bomb
Bostock-Cox, B. (2020) · Practice Nursing · doi:10.12968/pnur.2020.31.5.200
Griadil, T. I., Chopey, I. V., Дебрецені, К. О., Hechko, M. M., Mykhalko, Y. O., & Feysa, S. V. (2020) · Wiadomości Lekarskie · doi:10.36740/wlek202003109
Neue Empfehlungen zur Therapie des Typ-2-Diabetes
Müller‐Wieland, D. (2020) · CardioVasc · doi:10.1007/s15027-020-2106-z
Erhöhte Medikamenteneinkäufe von Apotheken bei Großhändlern in der Woche vor der Covid-19-Sperre
Kostev, K., & Lauterbach, S. (2020) · Monitor Versorgungsforschung · doi:10.24945/mvf.03.20.1866-0533.2226
Valensi, P. E. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.04.015
Paradigm shift in the management of DM & CVD —preventing the next CV event
Handelsman, Y., & Bloomgarden, Z. T. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13079
Guarding the glomerulus: Diabetes and the kidney
Bostock, B. (2020) · Independent Nurse · doi:10.12968/indn.2020.7.24
Introducing a novel therapy for type 2 diabetes to primary care
Brunton, S. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798686
Incretin-based treatment of diabetes and cardiovascular complications
Haluzı́k, M. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.012
Endocrinology and Covid-19: A Multifaceted Interaction
Priya, G., Grewal, E., & Maisnam, I. (2020) · Indian Journal of Cardiovascular Disease in Women · doi:10.1055/s-0040-1716787
Estrategia terapéutica en el paciente diabético (II). Hipoglucemiantes orales. Consejos al paciente
Hernández, E. L., Jiménez, P. G., & Mancebo-Sevilla, J. J. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.020 · Cited by 1
Gan, S., Dawed, A. Y., Donnelly, L. A., Nair, A. T. N., Palmer, C. N. A., Mohan, V., & Pearson, E. R. (2020) · Diabetes Care · doi:10.2337/dci20-0049
Komentár k ESC/EASD 2019 Odporúčaniam pre diabetes, prediabetes a kardiovaskulárne ochorenia
Fábryová, Ľ., Martinka, E., & Murín, J. (2020) · Cardiology letters · doi:10.4149/cardiol_2020_4_1
Nassar, H. M. A. (2020) · Suez Canal University Medical Journal · doi:10.21608/scumj.2020.123135 · Cited by 1
Cardiovascular and renal risk reduction in type 2 diabetes---which choice?
Drüeke, T. B. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.016
Lalau, J., Al‐Salameh, A., Wiernsperger, N. F., Goronflot, T., Pichelin, M., Wargny, M., Desailloud, R., Hadjad, S., Gourdy, P., & Cariou, B. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.02.013
New Trends: Time in Range and the Use of Continuous Glucose Monitoring Devices on Glycemic Control
Souza, K. L. V. D., Rassi, M. M. B., de Sá, D. A. R., Bussuan, R. M., Rodrigues, L. C. D. S., & Arbex, A. K. (2021) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2021.3.1.491
Maurantonio, M., Gabrielli, F., Castellano, C., Andrea, C., Andreoné, P., & Roncucci, L. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00035
Can biomarkers help find the ‘sweet spot’ for treating patients with diabetes?
Sattar, N. A., & Januzzi, J. L. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2175
A year in diabetic nephropathy
Tsoutsouki, J., & Chowdhury, T. A. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.293
Moderne Antidiabetika nach Metformin
Otto, C. (2021) · CME · doi:10.1007/s11298-021-2000-8
Khalimov, Y. S., St. Petersburg, R. F., Агафонов, П. В., Kuzmich, V. G., & Салухов, В. В. (2021) · Doctor Ru · doi:10.31550/1727-2378-2021-20-2-21-29
Aktuelle Empfehlungen zur Therapie bei Typ-2-Diabetes-mellitus
Müller‐Wieland, D. (2021) · Info Diabetologie · doi:10.1007/s15034-021-3702-4
Patoulias, D., Papadopoulos, C. E., & Doumas, M. N. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.05.002
GLP-1 receptor agonists: evolution and advancement in the treatment of type 2 diabetes mellitus
Candido, R. (2021) · The Journal of AMD · doi:10.36171/jamd21.24.2.4
Recommendations on the Clinical Trial Programme for Diabetes Medicines
Анатольевна, П. И., Petraneva, E. V., & Goryachev, D. V. (2021) · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · doi:10.30895/1991-2919-2021-11-2-94-103
Wojeck, B. S., & Inzucchi, S. E. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0070
Tsvetkova, A., & Mihaylova, S. G. (2021) · Journal of IMAB - Annual Proceeding (Scientific Papers) · doi:10.5272/jimab.2021273.3885
¿Por qué no insulinizamos cuando es necesario?
Simarro, F. L. (2021) · doi:10.52102/insulina/art-1 · Cited by 1
Cuándo y cómo iniciar la insulinización
Loiola, P. E. (2021) · doi:10.52102/insulina/art-2
Les nouvelles thérapeutiques du diabète
Larger, É., Paul, M., & Alexandre‐Heymann, L. (2021) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2021.09.018
Metformin-induced lactic acidosis in critically ill patients
Egi, M. (2021) · Journal of the Japanese Society of Intensive Care Medicine · doi:10.3918/jsicm.28_502
Metadata
- Authors
- Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of Copenhagen (DK)
- Università Cattolica del Sacro Cuore (IT)
- Universitair Ziekenhuis Leuven (BE)
- Duke University (US)
- University of Leicester (GB)
- Corresponding author
- Davies, Melanie J.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-19
- Volume
- 43
- Issue
- 2
- Pages
- 487-493
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6971782
- OpenAlex
- W4253996779
- Cited by
- 1,192
- References
- 21
- Citations by year
- 2026: 54 · 2025: 79 · 2024: 128 · 2023: 162 · 2022: 277 · 2021: 279 · 2020: 212
- FWCI
- 155.76
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-07-01)
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- Lirias (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Funders
- American Diabetes Association
- European Association for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- hyperglycemia management, type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors, major adverse cardiovascular events, heart failure hospitalization, heart failure with reduced ejection fraction, chronic kidney disease progression, HbA1c targets, cardiovascular risk stratification
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
